Summary
Type 2 Diabetes Mellitus (T2DM) is a metabolic health problem characterized by chronic hyperglycemia (higher blood glucose levels). Global prevalence has actually risen promptly in the past several decades, particularly in line along with obesity. This has actually been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and modifications in way of life patterns such as reasonable levels of bodily activity and consumption of higher-calorie diets.
This has actually led to tough commercial interest in the improvement of T2DM therapeutics. The most up to date market is large and diverse, comprising several drug classes, including generic and branded drugs. Owing to the range of therapeutic selections available, the treatment algorithm is complex. However, current treatment routines are regularly associated along with restricted long term efficacy, complex and inconvenient dosing regimens, and unhealthy edge effects such as weight obtain and hypoglycemia (reasonable blood glucose levels).
Get Sample Copy of Report along with TOC@ http://ift.tt/1TOSzIM
Scope
Metformin monotherapy will certainly stay the first-line pharmacotherapy for T2DM.
The emergence of several brand-new drug classes over the past decade, namely the Glucagon-Love Peptide-
1 (GLP-1) receptor agonists, Dipeptidyl Peptidase 4 (DPP-4) inhibitors, and Sodium–Glucose Cotransporter 2 (SGLT-2) inhibitors, has actually led to substantial market growth.
Which products lead these drug classes and exactly what threats do they face from the pipeline?
How will certainly the continued uptake of newer drug classes impact established drug classes such as the sulfonylureas and thiazolidinediones?
Leading insulin therapy Lantus (insulin glargine) recently lost patent protection in many serious markets.
Will recently approved insulin therapies such as Tresiba (insulin degludec) and Toujeo (insulin glargine) have the ability to capture a considerable section of Lantus’ market share?
The pipeline is large and highly innovative, comprising a range of molecule types and molecular targets.
How do various molecule types and molecular targets compare in terms of standard failure rate, clinical trial duration, and clinical trial size?
Which late-phase pipeline molecules reveal the many promise and Exactly how will certainly they impact the treatment algorithm over the forecast period?
Which late-phase pipeline molecules are expected to produce the highest revenues?
Over the 2014–2021 forecast period, the global T2DM market is expected to boost in value at a CAGR of 7.5% from $23.5 billion to $39.0 billion.
How do prevalence, diagnosis, and treatment patterns vary in the eight serious markets?
Which factors will certainly drive market growth many significantly?
Strategic consolidation activity in T2DM is considerable, along with US-based companies being essential players.
Do T2DM products usually attract higher levels of investment?
Understand the clinical context of the T2DM indication and the global burden of the health problem by interested in epidemiology, symptoms, etiology, pathophysiology, co-morbidities and complications, health problem classification, health problem prognosis, and treatment options
Appreciate The most up to date T2DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and understand gaps within the market and places of unmet need
Identify essential pipeline trends in molecule type and molecular target
Recognize the late-phase pipeline molecules that have actually demonstrated tough therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections
Consider market possibilities and potential risks by examining trends in T2DM clinical trial size, duration, and failure price by phase of development, molecule type, and molecular target
Discern variances in treatment usage patterns, annual therapy costs, and market growth projections for the US, Canada, the UK, France, Germany, Italy, Spain, and Japan
Discover Exactly how strategic consolidations have actually shaped The most up to date T2DM pipeline and marketed products landscapes
Make an enquiry @ http://ift.tt/24CeeuA
About Us
Market Research Store is a solitary destination for every one of the industry, firm and country reports. We feature large repository of latest industry reports, leading and niche firm profiles, and market statistics released by reputed private publishers and public organizations.
Contact Us:
Joel John
Deerfield Beach, Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
